MENU
+Compare
ATXS
Stock ticker: NASDAQ
AS OF
Oct 3 closing price
Price
$7.52
Change
-$0.17 (-2.21%)
Capitalization
424.39M

ATXS Astria Therapeutics Forecast, Technical & Fundamental Analysis

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases... Show more

Industry: #Biotechnology
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ATXS with price predictions
Oct 03, 2025

ATXS in upward trend: price rose above 50-day moving average on September 02, 2025

ATXS moved above its 50-day moving average on September 02, 2025 date and that indicates a change from a downward trend to an upward trend. In of 34 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 30, 2025. You may want to consider a long position or call options on ATXS as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The 50-day moving average for ATXS moved above the 200-day moving average on September 11, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ATXS advanced for three days, in of 256 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 189 cases where ATXS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ATXS moved out of overbought territory on September 12, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The Moving Average Convergence Divergence Histogram (MACD) for ATXS turned negative on September 19, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATXS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ATXS broke above its upper Bollinger Band on September 05, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ATXS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.569) is normal, around the industry mean (23.241). P/E Ratio (0.000) is within average values for comparable stocks, (54.537). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.239). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (354.169).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ATXS is expected to report earnings to fall 26.53% to -41 cents per share on November 12

Astria Therapeutics ATXS Stock Earnings Reports
Q3'25
Est.
$-0.42
Q2'25
Missed
by $0.08
Q1'25
Missed
by $0.13
Q4'24
Beat
by $0.01
Q3'24
Est.
$-0.42
The last earnings report on August 12 showed earnings per share of -56 cents, missing the estimate of -49 cents. With 771.19K shares outstanding, the current market capitalization sits at 424.39M.
A.I. Advisor
published General Information

General Information

a developer of new medicines for the treatment of cardiovascular, metabolic and inflammatory diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
75 State Street
Phone
+1 617 349-1971
Employees
59
Web
https://www.astriatx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FGIYX13.280.12
+0.91%
Nuveen Global Infrastructure I
AASOX18.610.09
+0.49%
Alger Small Cap Growth I-2
BISMX25.960.11
+0.43%
Brandes International Small Cap Equity I
VBCVX16.130.04
+0.25%
VALIC Company I Systematic Value
BILPX10.410.01
+0.10%
BlackRock Event Driven Equity Instl

ATXS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with XENE. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
-2.21%
XENE - ATXS
52%
Loosely correlated
+1.05%
CRNX - ATXS
51%
Loosely correlated
-1.57%
COGT - ATXS
51%
Loosely correlated
+6.85%
DNLI - ATXS
51%
Loosely correlated
+1.45%
NRIX - ATXS
50%
Loosely correlated
+3.30%
More